Hot News

Fosun Pharma Announces 2021 Interim Results Innovative Products Continuously Launched with International Operation Capability Further Improved

Highlights： Revenue amounted to RMB16,952 million, a year-on-year increase of 20.85%, of which, the income from regio...

Hot News

Sisram Medical Ltd, Announces Its Interim Results for the First Half of 2021 Accelerating its Wellness Eco-system Establishment, Harnessing Science and Technology to Lead the Global Medical Aesthetics Industry

Hong Kong, August 22, 2021 -- Sisram Medical Ltd (“Sisram”; stock code: 1696.HK; together with its subsidiaries referred as the “Group”), an operational holding company specializing in medical aesthetics technology for wellness, today announced its unaudited interim results for the six-month ended June 30, 2021 (the “Period”).

Hot News

Fosun Pharma Announces the Supply of 10 Million Doses of mRNA-based COVID-19 Vaccine to Taiwan Region

Hon Hai Precision Industry Co., Ltd. (“Hon Hai”), Yonglin Charity Foundation (“Yonglin”) and Zuellig Pharma, Inc. (“Zuellig Pharma”) respectively. Fosun Industrial will sell a total of 10 million doses of COVID-19 mRNA vaccines to Zuellig Pharma (pharmaceutical company with qualifications to import vaccines) entrusted by TSMC, Hon Hai and Yonglin. These COVID-19 mRNA vaccines will be donated to relevant agency of disease control of Taiwan region for local vaccination.

Hot News

Fosun Pharma Announces 2020 Annual Results Multiple Innovative Products Launched with Significant Improvement in the Capability of Global Commercialization

(29 March 2021, Shanghai, China) 29 March 2021, Shanghai Fosun Pharmaceutical (Group) Co., Ltd ("Fosun Pharma" or “the Group”; Stock Code: 600196.SH, 02196.HK), a leading healthcare group in China, announced its annual results for the year of 2020 ("the Reporting Period"), together with its 2020 Corporate Social Responsibility (CSR) report.